Nevertheless, this does not exclude potential therapeutic benefit from combination strategies involving a dual blockade of B7-H3 and PD-L1, particularly in patients with MSS-type CRC, where conventional immunotherapies based on anti–PD-1/PD-L1 monotherapy demonstrate limited efficacy. This evidence concerns the gene CD276 and colorectal carcinoma.